Quantum Genomics Sa Stock Market Capitalization
| ALQGC Stock | EUR 0.12 0.01 7.69% |
Quantum Genomics SA fundamentals help investors to digest information that contributes to Quantum Genomics' financial success or failures. It also enables traders to predict the movement of Quantum Stock. The fundamental analysis module provides a way to measure Quantum Genomics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Quantum Genomics stock.
Quantum |
Quantum Genomics SA Company Market Capitalization Analysis
Quantum Genomics' Market Capitalization is the total market value of a company's equity. It is one of many ways to value a company and is calculated by multiplying the price of the stock by the number of shares issued. If a firm has one type of stock its market capitalization will be the current market share price multiplied by the number of shares. However, if a company has multiple types of equities then the market cap will be the total of the market caps of the different types of shares.
Current Quantum Genomics Market Capitalization | 5.65 M |
Most of Quantum Genomics' fundamental indicators, such as Market Capitalization, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Quantum Genomics SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In most publications or references market cap is broken down into the mega-cap, large-cap, mid-cap, small-cap, micro-cap, and nano-cap. Market Cap is a measurement of business as total market value of all of the outstanding shares at a given time, and can be used to compare different companies based on their size.
| Competition |
Based on the recorded statements, the market capitalization of Quantum Genomics SA is about 5.65 M. This is 99.96% lower than that of the Biotechnology sector and 99.88% lower than that of the Health Care industry. The market capitalization for all France stocks is 99.97% higher than that of the company.
Quantum Market Capitalization Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Quantum Genomics' direct or indirect competition against its Market Capitalization to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Quantum Genomics could also be used in its relative valuation, which is a method of valuing Quantum Genomics by comparing valuation metrics of similar companies.Quantum Genomics is currently under evaluation in market capitalization category among related companies.
Quantum Fundamentals
| Return On Equity | -1.23 | |||
| Return On Asset | -0.48 | |||
| Operating Margin | (5.48) % | |||
| Current Valuation | (11.33 M) | |||
| Shares Outstanding | 34.53 M | |||
| Shares Owned By Insiders | 9.18 % | |||
| Shares Owned By Institutions | 3.69 % | |||
| Price To Earning | (5.10) X | |||
| Price To Book | 0.32 X | |||
| Price To Sales | 1.07 X | |||
| Revenue | 116.21 K | |||
| Gross Profit | (12.47 M) | |||
| EBITDA | (18.94 M) | |||
| Net Income | (17.36 M) | |||
| Cash And Equivalents | 5.01 M | |||
| Cash Per Share | 0.89 X | |||
| Total Debt | 283.69 K | |||
| Current Ratio | 3.36 X | |||
| Book Value Per Share | 0.44 X | |||
| Cash Flow From Operations | (17.02 M) | |||
| Earnings Per Share | (0.73) X | |||
| Target Price | 8.8 | |||
| Beta | 0.27 | |||
| Market Capitalization | 5.65 M | |||
| Total Asset | 22.59 M | |||
| Z Score | 11.4 | |||
| Net Asset | 22.59 M |
About Quantum Genomics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Quantum Genomics SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Quantum Genomics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Quantum Genomics SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Quantum Genomics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Quantum Genomics' short interest history, or implied volatility extrapolated from Quantum Genomics options trading.
Pair Trading with Quantum Genomics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Quantum Genomics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Quantum Genomics will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Quantum Genomics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Quantum Genomics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Quantum Genomics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Quantum Genomics SA to buy it.
The correlation of Quantum Genomics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Quantum Genomics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Quantum Genomics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Quantum Genomics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Quantum Genomics SA. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. Note that the Quantum Genomics information on this page should be used as a complementary analysis to other Quantum Genomics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Complementary Tools for Quantum Stock analysis
When running Quantum Genomics' price analysis, check to measure Quantum Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Quantum Genomics is operating at the current time. Most of Quantum Genomics' value examination focuses on studying past and present price action to predict the probability of Quantum Genomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Quantum Genomics' price. Additionally, you may evaluate how the addition of Quantum Genomics to your portfolios can decrease your overall portfolio volatility.
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Stocks Directory Find actively traded stocks across global markets | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |